GHP Family Pharmacy Customer Service 100 N. Academy Ave. Danville, PA 17822 Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com



## AUSTEDO (deutetrabenazine) PRIOR AUTHORIZATION FORM (form effective 01/03/2022)

Prior authorization guidelines for **VMAT2 Inhibitors** and **Quantity Limits/Daily Dose Limits** are available on Geisinger Health Plan's website at <a href="https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger">https://healthplan.geisinger.org/pharmacy/pharmacy/aspx?strip=true&style=OneGeisinger</a>

	Renewal request	Total # of pages:	Prescriber name:					
Name of office conta	Specialty:							
Contact's phone number:			NPI:			State license #:		
LTC facility contact/phone:			Street address:					
Beneficiary name:			Suite #: City/state/zip:					
Beneficiary ID#: DOB: Phone: Fax:								
CLINICAL INFORMATION								
Drug requested: Austedo tablet			Austedo Strength:					
Dose/directions:				Quanti	Quantity: Refills:			
Diagnosis (submit documentation):				Dx codes ( <u>required</u> ):				
All requests								
ALL requests  Do any of the following contraindications apply to the beneficiary? Check all that apply.  Submit supporting documentation,								
					1			
Actively suicidal  Taken an MAO inhibitor in the past 14 days				☐ Yes including liver function test (LFT)				
Hepatic impairment Taken reserpine in the past 20 days					□No results, mental health evaluation, and			
☐ Taking Xenazine or Ingrezza ☐ Depression that is untreated or inadequately treated <i>medication list.</i>								
		CYP2D6 metabolizer or will be		Yes Submit documentation of dosing and				
CYP2D6 inhibitor (such as bupropion, fluoxetine, paroxetine, or quinid			line), will the dose of No beneficiary's complete medication list.					
Austedo be adjusted	beneficially 8 complete medication has							
Is Austedo being pre	iatrist?							
		ΙΝΙΤΙΔΙ	requests	_				
Does the beneficiary	have one of the follow		•	numantation	oupportin	a honoficio	ru'a diagnosia	
Does the beneficiary have one of the following diagnoses?  Chorea associated with Huntington's disease			☐ Yes – Submit documentation supporting beneficiary's diagnosis. ☐ No – Submit medical literature documentation supporting the use of					
☐Tardive dy	Austedo for the beneficiary's diagnosis.							
Taruive uy	SKIIIGSIA		Tradicad for the born	onolary o all		0.1.1		
Did the beneficiary h			∐Yes ∐No	Submit evalua	t documentation of tion.			
If the beneficiary has a history of prior suicide attempt, bipolar disorder, or major depressive					□Yes	Submit	t documentation of	
disorder, was the beneficiary evaluated in the past 6 months and treated by a psychiatrist?					□No		tion and treatment.	
For the treatment of tardive dyskinesia, submit documentation of the following as it applies to the beneficiary:								
Has no other causes of involuntary movement  A dose decrease of dopamine receptor blocking agents is not appropriate								
Has documentation of TD severity								
RENEWAL requests								
Since starting Austedo, did the beneficiary experience an improvement in the medical condition							ation of beneficiary's	
being treated?			No response to therapy.					
Was the beneficiary reevaluated (and treated, if applicable) for new onset or worsening						oo to trioraj	٧٦٠	
-	•		☐Yes Submit documentation of evaluation.					
symptoms of depression and determined to be a candidate for treatment with Austedo?							) 4la a . a a ma l - 4 l	
Please submit to PromptPA https://ghp.promptpa.com OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.								

GHP Family Pharmacy Customer Service 100 N. Academy Ave. Danville, PA 17822 Tel. • 855•552•6028 PA Relay 711 GeisingerHealthPlan.com



Prescriber Signature:	Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.